SHAREHOLDERS' EQUITY (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014 Common Shares	Mar. 31, 2013 Common Shares	Mar. 31, 2014 Additional Paid-In Capital	Mar. 31, 2013 Additional Paid-In Capital	Mar. 31, 2014 Accumulated Deficit	Mar. 31, 2013 Accumulated Deficit	Mar. 31, 2014 Accumulated Other Comprehensive Loss	Mar. 31, 2013 Accumulated Other Comprehensive Loss	Mar. 31, 2014 Valeant Pharmaceuticals International, Inc. Shareholders’ Equity	Mar. 31, 2013 Valeant Pharmaceuticals International, Inc. Shareholders’ Equity	Mar. 31, 2014 Noncontrolling Interest	Mar. 31, 2013 Noncontrolling Interest	Dec. 31, 2012 Noncontrolling Interest
Increase (Decrease) in Shareholders' Equity
Beginning Balance (in shares)	333,036,637		333,000,000	303,900,000
Ending Balance	$ 5,233.3	$ 3,717.4	$ 8,301.2	$ 5,940.7	$ 228.8	$ 267.1	$ (3,278.5)	$ (2,371.0)	$ (132.8)	$ (119.4)	$ 5,118.7	$ 3,717.4	$ 114.6	$ 0	$ 0
Common shares issued under share-based compensation plans	3.5	2.6	15.0	11.6	(11.5)	(9.0)					3.5	2.6
Common shares issued under share-based compensation plans (in shares)			500,000	400,000
Repurchase of common shares		(35.0)		(9.8)				(25.2)				(35.0)
Repurchase of common shares (in shares)				(500,000)
Share-based compensation	24.8	9.1			24.8	9.1					24.8	9.1
Employee withholding taxes related to share-based awards	(27.7)	(6.8)			(27.7)	(6.8)					(27.7)	(6.8)
Tax benefits from stock options exercised	1.2	4.6			1.2	4.6					1.2	4.6
Acquisition of noncontrolling interest	(3.3)				(1.1)						(1.1)		(2.2)
Total before comprehensive income (loss)	5,231.8	3,691.9	8,316.2	5,942.5	214.5	265.0	(3,278.5)	(2,396.2)	(132.8)	(119.4)	5,119.4	3,691.9	112.4
Total before comprehensive income (loss) (in shares)			333,500,000	303,800,000
Comprehensive loss:
Net loss	(20.3)	(27.5)					(22.6)	(27.5)			(22.6)	(27.5)	2.3
Other comprehensive loss	(8.0)	(77.4)							(7.2)	(77.4)	(7.2)	(77.4)	(0.8)
Comprehensive loss	(28.3)	(104.9)									(29.8)	(104.9)	1.5
Beginning Balance (in shares)	333,520,028		333,500,000	303,800,000
Ending Balance	$ 5,203.5	$ 3,587.0	$ 8,316.2	$ 5,942.5	$ 214.5	$ 265.0	$ (3,301.1)	$ (2,423.7)	$ (140.0)	$ (196.8)	$ 5,089.6	$ 3,587.0	$ 113.9	$ 0	$ 0